Novozymes Biopharma supplies Neomend with albucult for use in ...

More documents

Recommendations

Info

“Novozymes is delighted that Neomend has selected albucult for use inits unique sealant technology”, says Dermot Pearson, MarketingDirector, Novozymes Biopharma. “The partnership demonstratesNovozymes’ commitment to providing quality materials for use in thehealthcare, pharmaceutical and biotechnology industries and allows thecompany to position itself as a reliable partner in the wound sealant andmedical device markets.”The use of albucult in ProGEL PLATINUM and other medical devicesconfers a range of unique advantages not possible with animal-derivedingredients such as sustainability of supply, GMP compliance andimproved biocompatibility. Albucult also delivers unprecedentedperformance and quality benefits to medical applications includingsealants, device coating and cell therapy applications while ensuringbatch-to-batch consistency which can significantly reduce lot testingburdens for customers.For further information on Novozymes products, please visitwww.biopharma.novozymes.com###About Neomend, Inc.Neomend, based in Irvine, California, is a private company focused on the design,development and commercialization of surgical sealants and adhesion prevention productsderived from the ProGEL technology platform. The company has a direct sales force of 30people in the U.S. and holds 28 issued U.S. patents in chemical composition and deliveryapplicators. For more information, visit www.Neomend.com or call 949-916-1630.About NovozymesNovozymes is the world leader in bioinnovation. Together with customers across a broadarray of industries, we create tomorrow’s industrial biosolutions, improving our customers'business and the use of our planet's resources.With over 700 products used in 130 countries, Novozymes’ bioinnovations improveindustrial performance and safeguard the world’s resources by offering superior andsustainable solutions for tomorrow’s ever-changing marketplace. Read more atwww.novozymes.com.Contact:Novozymes Biopharma:Sally Vernon, Customer Communications ManagerSYKE@novozymes.comTel. +44 115 955 3355Page 2 of 3Novozymes · Krogshoejvej 36 · 2880 Bagsvaerd · Denmark · Tel. +45 4446 0000 · www.novozymes.com
MEDIA CONTACTSEuropeAnnegrethe Møller JakobsenOffice: +45 4446 3050Mobile: +45 3077 3050agmj@novozymes.comChinaZhu XiaoqingOffice: +86 106 2987888+362Mobile: +86 138 012 40590xqzh@novozymes.comUSPaige DonnellyOffice: +1 919 494 3209Mobile: +1 919 218 4501pagd@novozymes.comBrazilSaionara Ribeiro de PaulaOffice: +55 41 3641 1112Mobile: +55 41 9971 7225saio@novozymes.comINVESTOR CONTACTSEuropeTobias BjorklundOffice: +45 4446 8682Mobile: +45 3077 8682tobb@novozymes.comUSThomas Steenbech BomhoffMobile: +1 919 649 2565tsbm@novozymes.comPage 3 of 3Novozymes · Krogshoejvej 36 · 2880 Bagsvaerd · Denmark · Tel. +45 4446 0000 · www.novozymes.com
Page 1: Novozymes Biopharmasupplies Neomend

Novozymes Biopharma supplies Neomend with albucult for use in ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?